Global News

EMA approves GSK’s Malaria vaccine

Wednesday, July 29, 2015

GlaxoSmithKline (GSK) has received a positive opinion for its malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The vaccine candidate Mosquirix (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision.

[Read More]

Greenphire appoints Sue Vestri new chief financial officer

Wednesday, July 29, 2015

Greenphire, a King of Prussia, Pa.-based provider of payment technologies for the clinical trials industry, has appointed Sue Vestri as chief financial officer. Vestri will be responsible for developing and driving the financial strategy for Greenphire, including working with the senior team to drive the company’s mission and help execute its growth plans.

[Read More]

Progenics receives FDA Breakthrough Therapy for Azedra

Wednesday, July 29, 2015

The FDA has designated Progenics Pharmaceuticals’ Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra currently is being evaluated in a pivotal phase IIb trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received Orphan Drug and Fast Track designations from the FDA.

[Read More]

Sanofi, Regeneron collaborate on immuno-oncology

Wednesday, July 29, 2015

Sanofi and Regeneron Pharmaceuticals have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. The two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in phase I testing, and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.

[Read More]